Percocet Pill

Phase 3Small molecule

UUniversity of Manitoba

Percocet Pill is one of 26 small molecule programs targeting Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaActive, not recruiting

HyperplasiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Hyperplasia

#DrugCompanyPhaseTrials

Lialda

Takeda

Approved

1 2

Nolvadex

Megace

4 4

Propecia

Flomax

2 6

Vesicare

Astellas

Phase 3

1 7

Femara

Novartis

Phase 3

1 8

Victoza

Novo Nordisk

Phase 3

1 9

Ativan

BBausch Health Americas, Inc.

Phase 3

1 10

Gnrh Ant

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Popliteal Nerve Block1 trial

Effect of Ropivacaine During Popliteal Nerve Block in Foot and Ankle Surgery

Unknown status·RRothman Institute Orthopaedics·Phase 3·NCT04872322·128 enrolled

Hyperplasia1 trial

Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia

Not yet recruiting·UUniversity of Manitoba·Phase 3·NCT07017452·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Percocet Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Percocet Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Percocet Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Manitoba company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Manitoba

Percocet Pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Popliteal Nerve Block1 trial

Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News